Table 7.

Quantitative synthesis of controlled pharmacological studies sorted by risk of bias assessment

	RoB	Primary endpoint	Baseline vs. end of treatment
			d [95% CI]
			Verum	Placebo
Nicoli de Mattos et al. (2020)	56	YBOCS-SV	−1.65 [−2.36, −0.95]	−1.17 [−1.80, −0.54]
Black et al. (2000)	28	YBOCS-SV	−1.12 [−1,98, −0.26]	−1.15 [−2.05, −0.24]
Koran et al. (2003)a	28	YBOCS-SV	−0.66 [−1.74, 0.41]b	1.77 [0.62, 2.93]b
Ninan et al. (2000)	26	YBOCS-SV	−1.39 [−2.08, −0.70]	−1.56 [−2.33, −0.79]

Note. RoB = risk of bias based on CONSORT criteria (higher scores indicate lower risk of bias), YBOCS-SV = Yale-Brown Obsessive-Compulsive Scale.

Cohen's d and 95% confidence intervals (CI) are reported. All based on published intention-to-treat analyses. Negative d_YBOCS-SV indicate the effect size of improvement in compulsive buying-shopping disorder symptoms. ^adouble-blind discontinuation phase of an open-label study.

The findings of the double-blind discontinuation phase reported by Koran et al. (2007) are not included in the quantitative synthesis because YBOCS-SV means and SDs were not provided by group.